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Abstract
Background: Chondrosarcoma is the second most frequent primary malignant bone tumor. Treatment is mainly
based on surgery. In general, wide resection is advocated at least in G2 and G3 tumors. But which margins should
be achieved? Does localization as for example in the pelvis have a higher impact on survival than surgical margins
themselves?
Methods: From 1982 to 2014, 87 consecutive patients were treated by resection. The margin was defined as R0
(wide resection), R1 (marginal resection) or, R2 if the tumor was left intentionally. All patients were followed for
evidence of local recurrence or distant metastasis. Overall and recurrence-free survival were calculated, significance
analysis was performed.
Results: In 54 (62%) cases a R0 resection, in 31 (36%) a R1 and in 2 (2%) patients a R2-resection was achieved.
Histology proved to be G1 in 37 patients (43%), G2 in 41 (47%) and G3 in 9 cases (10%). 5-year local recurrence-free
survival (LRFS) was 75%. Local recurrence-free survival showed a significant association with the margin status and
the localization of the tumor with pelvic lesions doing worst. Metastatic disease was initially seen in 4 patients (4.
6%), 19 others developed metastatic disease during follow-up. Overall survival of the entire group at 5 and 10 years
were 79 and 75%, respectively. The quality of surgical margins and the presence of local recurrence did not
influence overall survival in a multivariate analysis. Pelvic lesions had a worse prognosis as did higher grades of the
tumor, metastatic disease and age.
Conclusions: The mainstay of therapy in Chondrosarcoma remains surgery. Risk factors as grading, metastatic
disease, age and location significantly influence overall survival. Margin status (R0 vs. R1) did influence local
recurrence-free survival but not overall survival. Chondrosarcomas of the pelvis have a higher risk of local
recurrence and should be treated more aggressively.
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Background
Following Osteosarcoma, chondrosarcoma (CS) is the sec-
ond most frequent primary malignant bone tumor ac-
counting for approximately 20% of all bone sarcomas [1].
It constitutes a heterogeneous group of tumors character-
ized by the production of cartilaginous matrix [2]. Central
(conventional) CS represents about 75% of the group.
With the introduction of the current WHO classification
in 2013 Chondrosarcoma grade I (now officially termed
atypical cartilaginous tumor) was reclassified as an inter-
mediate (locally aggressive) tumor, better reflecting its
clinical behavior [2]. In these difficult cases, the differen-
tial diagnosis towards benign enchondromas is based on a
combination of pathology, radiology and clinical features
and hence requires a close multidisciplinary assessment
[3].
Treatment is mainly based on surgery and chemother-
apy is less effective because of a low mitotic index and
poor vascularity [4, 5]. Radiotherapy is effective but re-
quires substantial dosage [6].
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In general, wide resection is advocated at least in G2
and G3 tumors. It is assumed that patients with CS have
an excellent prognosis after adequate surgery [4] but
reviewing the literature and our own results, such as-
sumptions should be looked at in a more detailed fashion.
Even the G1 lesions have a risk of metastasis of 6% [7].
There is no clear consensus on what exactly constitutes
“adequate surgery”. Which margins should be achieved?
Does localization as for example in the pelvis have a
higher impact on survival than surgical margins taken for
themselves? In a metaanalysis on 1114 patients published
in 2015, the surgical margin were not identified as an in-
dependent predictor of overall survival [8]. In conse-
quence, the traditional dogma of adequate margins, as
stated by some authors [9, 10] had to be called into
question.
The main aim of this retrospective study was to
analyze a homogenous group of patients with primary
central CS of bone, treated at a single tumor center. We
sought to determine prognostic factors for overall and
local recurrence-free survival. Secondary aim was to
asses our own results on the background of the pub-
lished data.
Methods
From 1982 to 2014, 87 consecutive patients with chondro-
sarcoma of the extremities, pelvis and trunk wall were
treated at our institution. All tumors had a diagnosis of
chondrosarcoma based on histological features and
immunohistochemistry.
Prior to surgical resection, predominantly magnetic res-
onance imaging (MRI) and in some cases computed tom-
ography (CT) was used to define size and localization of
the tumor. A CT scan of the chest was performed to de-
termine the presence or absence of metastatic disease.
All patients underwent surgical resection. The margin
was defined as R0 if a rim of healthy tissue around the
lesion was present (wide resection) or R1 if the margins
were contaminated but the tumor capsule remained
closed (marginal resection). In select patients, a planned
partial resection was performed in order to avoid se-
verely mutilating surgery. This was classified as a R2
resection.
Statistical analysis
All patients were followed for evidence of local recur-
rence (LR) or distant metastasis in general by regional
MRI scans and chest radiographs. Clinical outcomes of
local recurrence (LR), local recurrence-free survival
(LRFS) and overall survival (OS) were used for assess-
ment. LRFS and OS were defined either as the time from
surgery to the first occurrence of local recurrence or to
death from any cause. For statistical analysis, overall and
local recurrence-free survival were calculated according
to the Kaplan-Meier method. Significance analysis was
performed using the Log-Rank, the Chi-Square test or
the Cox proportional-hazards regression model. A P
value of less than 0.05 was considered statistically signifi-
cant. The data analysis software used was MedCalc®
(MedCalc Software, Ostend, Belgium).
Results
The median age of the 54 male and 33 female patients
was 51.7 years (mean 50.3, range 15–83). The lower ex-
tremity was involved in 44 cases (29 femur, 18 of them
proximal; 11 tibia, 10 of them proximal; fibula and feet 2
each), the upper extremity in 10 (7 humerus, 5 of them
proximal; radius, ulna and hand 1 each), the pelvis in 21
and the trunk in 12 (8 scapula, 2 ribs, clavicle and thor-
acic spine 1 each) patients. Fifty patients (57.5%) showed
extraosseous tumor growth.
The median duration of symptoms prior to diagnosis
was 9 months (range, 0–358) and the majority of pa-
tients (44 = 52%) complained of pain, 11 (13%) of swell-
ing. A pathologic fracture led to the diagnosis in 6 (7%)
patients. Neurological impairment or restriction of
movement was seen occasionally. 70 (81%) patients had
a biopsy or histology before surgery. In 2 cases, the bi-
opsy was interpreted as a cartilaginous exostosis and in
3 cases as an enchondroma. Four patients had already
undergone surgery at other institutions by means of
intramedullary nailing or by resection and endopros-
thetic reconstruction. In these cases, the tumor had ei-
ther gone unidentified or it had been underestimated.
Only 4 patients had metastatic disease initially.
Resections of the tumor alone were performed in 42
cases (48%), resections and reconstructions with mega-
endoprostheses in 24 cases (28%), amputations in 11 pa-
tients (13%) and curettages in 10 instances (11%). A
wide (R0) resection was performed in 54 (62%) cases, a
marginal (R1) resection in 31 cases (36%) and an
R2-resection in 2 (2%) patients. With pelvic lesions, 48%
of surgical margins were either R1 or R2, at the lower
extremity 41%, at the upper extremity 20% and at the
trunk 25% (n.s.). Histology proved to be G1 in 37 pa-
tients (43%), G2 in 41 (47%) and G3 in 9 cases (10%).
In 20 patients (23%), surgical revisions due to compli-
cations had to be performed. This included:
Nine revisions due to dislocation or loosening of im-
plants or bone grafts, 6 deep infections, 2 hematomas,
and more aggressive tumor resection, neurological im-
pairment and vessel injury in 1 case each.
In 63 surviving patients, the median follow-up time
from surgery to last information on the patient was
68 months (range, 0–379). One patient was lost to
follow-up less than 12 months after surgery, 8 patients
had a follow-up of 12–24 months. Twenty-four patients
deceased during follow-up.
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Five-year local recurrence-free survival was 75%. In
total, 21 (24%) patients developed local recurrences, of
which 52% occured in the first 12 months and 81% in
the first 24 months after surgery (Fig. 1). The latest LR
was seen after 10 years. Local recurrence-free survival
showed a significant association with the margin status
and the localization of the tumor with pelvic lesions
doing worst (Table 1, Figs. 2 and 3). In multivariate ana-
lysis, both kept significance.
Metastatic disease was initially seen in 4 patients
(4.6%). One of those patients stayed free of disease after
resection, 19 others developed metastatic disease during
follow-up. At final follow-up, 22 (23%) patients had
metastatic disease, 13 of which were located in the lung,
3 in the spine, one in the femur, one in visceral organs
and 4 in multiple localizations. Only 5 of these patients
were alive with disease at final follow-up. Of these 22
patients with metastatic disease, only 8 also had a LR
(36%) whereas 20% of non-metastasized patients had LR
which was not statistically significant. Grading showed a
trend towards metastatic disease in follow-up with 14%
in G1, 30% in G2 and 44% in G3 tumors but without
statistical significance (p = 0.0815).
Overall survival of the entire group at 5 and 10 years
was 79 and 75%, respectively. Grading proved to be a
significant factor (Fig. 4, p = 0.0099) as was metastatic
disease (Fig. 5, p < 0.0001). Local recurrence also had a
strong effect (Fig. 6a, p = 0.0219). Regarding margin sta-
tus (Fig. 6b, n.s.) and localization (Fig. 7) only the latter
had an influence on survival (p = 0.0008).
Table 1 Factors influencing local recurrence (margin status, location) and local recurrence free survival
Local recurrence No Yes p-value 5-year LRFS 10-year LRFS p-value
R0 45 (83%) 9 (17%) 0.1025* 84.7% 81.4% 0.0204+
R1 20 (65%) 11 (35%) 61.9% 61.9%
R2 1 (50%) 1 (50%) 0% 0%
Upper Extremity 10 (100%) 0 (0%) 0.0568* 100% 100% 0.053+
Lower Exremity 35 (80%) 9 (20%) 79.0% 79.0%
Pelvis 12 (57%) 9 (43%) 55.7% 44.7%
Trunk 9 (75%) 3 (25%) 75.0% 75.0%
*Chi-squared test;
+Logrank test
Fig. 1 Local recurrence-free survival in 87 patients with central chondrosarcoma
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In general, male and female patients showed no differ-
ence whereas age with a cut-off of 50 years was a signifi-
cant predictor of outcome (Fig. 8, p = 0.019).
As shown in Table 2, the quality of surgical margins
and the presence of local recurrence did not influence
overall survival in a multivariate analysis. Pelvic lesions
led to a worse prognosis as did higher tumor grade,
presence of metastatic disease and greater age.
Discussion
Age in general is a very strong factor of overall survival
as shown in data out of the SEER Database (USA) [11].
Fig. 3 The impact of tumor localization on local recurrence-free survival (p = 0.0532)
Fig. 2 The impact of surgical margins on local recurrence-free survival in R0 and R1 resected patients (p = 0.05)
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Fig. 5 Metastatic disease in 22 patients significantly deteriorates overall survival (p < 0.0001)
Fig. 4 Overall survival is strongly influenced by tumor grading (p = 0.0099)
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Location is undoubtedly also an important aspect. As
highly significantly shown in our data, pelvic location of
a chondrosarcoma has a worse prognosis. This kept sig-
nificance also in multivariate analysis. Our 5 and 10-year
survival rates in those patients are 50 and 42%, respect-
ively. In central chondrosarcomas, published 10-year
survival rates vary between 54 and 88% [12–17]. This
variability in survival depends very much on whether
peripheral chondrosarcomas were included and how
many patients in the study group had a low-grade chon-
drosarcoma or recurrent disease. Regarding margins, in
pelvic lesions these were associated with LR [12, 13, 16,
17] but not OS [12, 15, 17]. In other studies LR did
clearly influence OS [12–14]. However, the opposite ob-
servation, indications that LR did not influence OS has
also been published [16]. Some authors showed that LR
influenced metastatic disease and hence secondarily OS
[13].
The main conclusion in summarizing the published lit-
erature and our own data is, that chondrosarcoma of the
pelvis does exhibit a more aggressive behaviour and
should not be curetted even in low-grade tumors. Local
recurrence might lead to dedifferentiation and metastatic
disease.
In general, low-grade central CS showed a good progno-
sis with a 5- and 10-year OS of 97 and 92%. But 5 of our
Fig. 6 a Local recurrence in 21 patients reduces overall survival (p = 0.0219). b The surgical margin (R2 only 2 cases) does not influence overall
survival (n.s)
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37 patients (14%) developed LR and 6 (16%) developed
metastatic disease (MD), 4 of which eventually (11%) died
from it. The published data on G1 chondrosarcoma is
conflicting. From 0% LR and MD [18, 19], 2% LR and 0%
MD [20], 3% LR and 3% MD [21], 4% LR and 0% MD
[22], 5% LR and 0% MD [23], 6% LR and 0% MD [24, 25],
9% LR and 0% MD [26], 11% LR and 3% MD [27], 13% LR
and 4% MD [28], 13% LR and 5% MD [29] to 18% LR and
6% MD [7] a variety of different results are reported.
5-year survival ranges from 82 to 99% and 10-year survival
from 89 to 95% [8]. This reflects the problem of differenti-
ation of benign enchondromas and atypical cartilaginous
Fig. 7 A pelvic location is worse in respect to overall survival (p = 0.0008)
Fig. 8 Overall survival is worse in patients older than 50 years (p = 0.019)
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tumor and the heterogenous distribution of therapy and
localization in these studies [3, 30–32]. Bauer et al. treated
40 patients with enchondromas and 40 patients with
low-grade CS. His results showed no difference between
groups [33]. So intralesional curettage with and without
adjuvants is a valid option in most of those patients, but
as stated above, central lesions should be resected because
of their higher recurrence rates [27].
Metastatic disease was seen in 23%. This is about the
same as described by other authors [10, 34–36]. There
are series with a lesser [37, 38] or a higher [16, 39] pro-
portion of metastatic disease. This reflects the import-
ance of patient selection. The inclusion of initially
non-metastasized patients only, patients with G2/3 le-
sions only or patients with axial or pelvic localizations
only has a strong impact on MD and survival. In general
MD is bad news for the patient with a 5-years overall
survival of less than 50%. As shown in Table 2, MD is
the most significant negative prognostic factor. There
are patients, in whom metastatic disease is manageable
by resection, local radiation or systemic therapy, leading
to survival rates of 10–30% after 10 years, as also in this
study. But this is the exception, mainly seen in G1 tu-
mors [9, 34, 40]. Our results show, that MD is more
common in G2/3 lesions as described by others [9, 34,
39, 41] but it is independent from surgical margins with
the same rate of MD in R0 and R1 resected patients,
and also independent from LR. This is in some respect
in contrast to the literature [9, 10, 35] but other authors
did see the same, confirming grade and location [42] as
risk factors or grade as the only significant risk factor
[16] for MD in multivariate analyses. In a large survey in
Finland [36] the decade of diagnosis was the only signifi-
cant factor on MD with an increased risk in the 1980s.
One of the most urgent questions is which margin
should be obtained and how does margin influence LR
and OS. In our study, local recurrence-free survival was
significantly associated with margin status and LR influ-
enced OS as in most of the published studies [9, 35, 43].
But in our data as well as in previous publications, LR
and margin status showed no effect on overall survival
in multivariate analysis [34]. We have to admit, that we
only could include 2 cases with a R2 margin. Those
seem to have a worse prognosis. There are not many
studies including margin status in a multivariate analysis
of overall survival [7, 10]. Lee shows a significant impact
of margins on overall survival for patients with
high-grade CS but the curves for wide and marginal re-
sections did separate only after 120 months with just
two events in the marginal group later on [10]. Fiorenza
in 2002 reported findings identical to ours, namely a sig-
nificant influence of LR on OS in univariate analysis and
no influence of margin status in multivariate analysis [9].
LR remained significant as did grade and location. So in
concordance with other groups, we conclude that LR
after adequate resection is more likely to be a marker of
the aggressiveness of the tumor than a consequence of
failed local therapy [34, 44, 45]. We still maintain the
premise of adequate resection, but some authors state
that also intracompartmental grade 2 chondrosarcomas
with a non-aggressive radiologic pattern can be treated
by curettage without negatively affecting prognosis [46].
In patients with local recurrence but without MD, fur-
ther aggressive surgery appears to constitute a good
chance of cure (64% published by Fiorenza et al.) [9].
Conclusions
The mainstay of therapy in chondrosarcoma of bone is
surgery. Risk factors such as tumor grading, metastatic
disease, age and location significantly influence overall
survival. Margin status did influence local recurrence-free
survival but not overall survival. Regarding the latter, the
literature is inconclusive mainly due to a large heterogen-
eity of the study populations. Chondrosarcomas of the
pelvis have a higher risk of local recurrence and should
therefore be treated more aggressively at least to avoid
local complications.
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Variables Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Grading 2532 (1360-4715) 0,0034 3208 (1380-7457) 0,0067
Metastatic disease 11,477 (4,6288-28,4589) < 0,0001 14,763 (4819-45,229) < 0,0001
Age < =50 2906 (1143-7389) 0,0251 0,307 (0,115-0,822) 0,0188
Margin status 1311 (0,642-2678) 0,4571 1152 (0,4997-2655) 0,7401
Pelvic/Non-pelvic 0,309 (0,165-0,578) 0,0002 0,441 (0,231-0,845) 0,0136
Local recurrence 2614 (1115-6125) 0,0270 1233 (0,448-3394) 0,6847
P-values in bold indicates significance
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